Breast conservative surgery, along with radiotherapy or mastectomy, remains the standard of care in early-stage breast cancer, with or without adjuvant systemic therapeutic administration, which relies on the status of lymph nodes, hormone receptors, as well as human epidermal growth factor receptor-2 (HER-2) [12]. The gene discussed is NR4A1; the disease is breast cancer.